Clinical trial
Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity…
NCT00254293 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00254293 |
|---|---|
| Title | Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA) |
| Official title | A Study to Assess the Steady-State Trough Serum Concentration, Safety, and Immunogenicity of Abatacept (BMS-188667) Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Who Are Receiving Disease Modifying Ant-Rheumatic Drugs (DMARDs) |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Abatacept or Placebo (both as IV & SC Solution), Abatacept or Placebo (both as IV & SC solution), Abatacept |
| Enrollment | 87 |
| Start date | Jan 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | Jul 1, 2012 |
| First posted | Nov 16, 2005 |
| Last update posted | Apr 8, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: